ASBM/GaBI 2022 biosimilar webinar on non-medical switching

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

ASBM/GaBI 2022 biosimilar webinar on non-medical switching

Home/Conferences | Posted 03/06/2022 0 Post your comment

NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US
Overview of Non-Medical Switching Practices in Different Regions and the Importance of Safeguarding the Physician–Patient Relationship
20 July 2022 | WATCH REPLAY

ASBM 2022 Webinar 2 Banner Square V22G29 replay

The advent of biologicals offers significant benefits and enhanced quality of life for patients with chronic diseases, such as rheumatoid arthritis, multiple sclerosis and cancer. However, finding a working treatment regimen may take a long time and involves trial and error for a patient’s individual case.

Nevertheless, government policies that force biosimilar switching for non-medical and strictly economic reasons may ultimately affect patients’ treatment and their well-being, create mistrust in the healthcare system, undermine competition, increase total healthcare costs, and act as a barrier to innovation and future access to new biological drugs for patients.

Non-medical switching should consider two governing principles: 1) the physician–patient relationship must be protected to ensure the best outcomes; and 2) patients stabilized on a biological therapy should not be forced to undergo a non-medical switch.

In this online event, we shared the expert experience and knowledge on medical switching and principles and guidance on interchangeability of biologicals/biosimilars, highlighting the specific concerns on, and the importance of a multi-stakeholder approach protecting the physician–patient relationship in the practice of non-medical switching of biologicals/biosimilars.

The webinar was held on 20 July 2022 – 10:00 am to 12:00 pm EDT.

The First Webinar on KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS: EUROPE AND THE US had 244 registrants/attendees; seats are limited to 250 in this 2nd webinar on non-medical switching of biologicals/biosimilars.

SPEAKERS:
Michael S Reilly, Esq, Executive Director, Alliance for Safe Biologic Medicines, USA
Gail Attara, President & Chief Executive Officer, Gastrointestinal Society, Canada
Ralph McKibbin, MD, FACP, FACG, AGAF, Past President of the Pennsylvania Society of Gastroenterology and the Digestive Disease National Coalition, USA
Leah Christl, PhD, Amgen, USA (Former FDA Director at CDER), USA
Durhane Wong-Rieger, PhD, Canadian Organization for Rare Disorders, Canada
Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, Ohio State University, USA

Panel discussion and Q&A
Steven Stranne, MD, JD, Foley Hoag LLP, USA
Michael S Reilly, Esq, USA
Jaymee Maaghop, Gastrointestinal Society, Canada
Ralph McKibbin, MD, FACP, FACG, AGAF, USA
Leah Christl, PhD, USA
Urvashi Rathod, International Federation on Ageing, Canada

Download speakers bio and presentations

Check out the registrants profile here!

Online event hosted by the Alliance for Safe Biologic Medicines and Generics and Biosimilars Initiative

WATCH OUT!
ASBM–GABI Biosimilar Webinar Series
The discussion will continue at the next webinar on 'Ophthalmic Biosimilars'. Contact us for more information.

View all events